Subsequent in silico analysis of the top-ranked neoepitopes showed that they each contain a predicted strong binder for H-2d class I alleles in addition to the class II binder, thus potentially able to induce both CD4+ and CD8+ T-cell responses as is reported to be essential in murine models of cancer immunotherapy (Supplementary Table 1)18,35. The gene discussed is CD4; the disease is cancer.